转移性前列腺癌中的PARP抑制剂:当前证据与未来方向。
完整摘要 · 中文译文
聚(ADP-核糖)聚合酶抑制剂(PARPis)是同源重组修复基因改变的转移性前列腺癌的既定治疗方法。PARPis的疗效——无论是作为单药还是与雄激素受体通路抑制剂(ARPIs)联合——最初是在转移性去势抵抗性前列腺癌(mCRPC,近期称为雄激素通路调节抵抗性[APMR]前列腺癌)患者中确立的,在BRCA2改变性疾病中观察到最大获益。本综述重点关注由AMPLITUDE和TALAPRO-3试验(分别评估尼拉帕利和他拉唑帕利)产生的、关于PARPis联合标准治疗ARPIs和雄激素剥夺治疗对转移性激素敏感性前列腺癌(mHSPC,也称为雄激素通路调节敏感性[APMS]前列腺癌)患者获益的更新证据。PARPis将以多广泛的程度纳入mHSPC/APMS患者的临床管理,将取决于对以下问题的认识:最佳患者资格(包括生物标志物选择)、短期和长期治疗相关不良事件、其他可用治疗选择以及治疗序贯。本综述还探讨了PARPi治疗mHSPC/APMS疾病状态的未来方向,包括正在进行的评估PARP1选择性药物saruparib的EvoPAR-Prostate01 3期注册试验。
完整摘要 · 英文原文
Inhibitors of poly(ADP-ribose) polymerase (PARPis) are an established treatment for homologous recombination repair gene-altered metastatic prostate cancer. The efficacy of PARPis-both as single agents and in combination with androgen receptor pathway inhibitors (ARPIs)-was first established in patients with metastatic castration-resistant prostate cancer (mCRPC, more recently termed androgen pathway modulation-resistant [APMR] prostate cancer), with the greatest benefit observed in BRCA2-altered disease. This review focuses on the more recently demonstrated evidence of the benefit of PARPis in combination with standard-of-care ARPIs and androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC, also termed androgen pathway modulation-sensitive [APMS] prostate cancer) generated by the AMPLITUDE and TALAPRO-3 trials, which evaluated niraparib and talazoparib, respectively. How broadly PARPis will be incorporated into the clinical management of patients with mHSPC/APMS will depend on the perception of issues such as optimal patient eligibility (including biomarker selection), short- and long-term treatment-related adverse events, other available treatment options, and treatment sequencing. The review also examines future directions for PARPi therapy for the mHSPC/APMS disease state, including the ongoing EvoPAR-Prostate01 phase 3 registration trial evaluating the PARP1-selective agent saruparib.